Time To Definitive Deterioration In Patients With Metastatic Breast Cancer Subjected To Second-Line Monochemotherapy.

e12504Background: Since metastatic breast cancer (MBC) is incurable, main goals of chemotherapy (CT) are the recovery and maintenance of patient health-related quality of life (HRQOL), the reduction of symptoms related with the disease and prolonging life. In this context, time to definitive deterioration (TDD) has been proposed as a modality of longitudinal HRQOL analysis for cancer patients. To date, few studies have focused in the analysis of TDD in patients with MBC treated with 2nd-line CT in a context of normal medical practice. Methods: A prospective observational study performed in 87 MBC patients (100 patients recruited; 50% of total planned) who initiated 2nd-line monoCT in 30 Spanish hospitals. Using the EORTC-QLQ-C30 questionnaire, the breast module QLQ-BR23 and the CT-induced peripheral neuropathy (CIPN) module, HRQOL was assessed at the beginning of CT and every three months thereafter until disease progression and/or treatment (TX) discontinuation. TDD was considered when HRQOL decrease 5% ...